DK0495265T3 - Syrelabile koblingsmolekyler - Google Patents
Syrelabile koblingsmolekylerInfo
- Publication number
- DK0495265T3 DK0495265T3 DK91203439.4T DK91203439T DK0495265T3 DK 0495265 T3 DK0495265 T3 DK 0495265T3 DK 91203439 T DK91203439 T DK 91203439T DK 0495265 T3 DK0495265 T3 DK 0495265T3
- Authority
- DK
- Denmark
- Prior art keywords
- aralkyl
- aryl
- lower alkyl
- acid
- alkylene
- Prior art date
Links
- 230000008878 coupling Effects 0.000 title 1
- 238000010168 coupling process Methods 0.000 title 1
- 238000005859 coupling reaction Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 239000000126 substance Substances 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 229940127121 immunoconjugate Drugs 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Mushroom Cultivation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP90203526 | 1990-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0495265T3 true DK0495265T3 (da) | 1995-01-02 |
Family
ID=8205218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK91203439.4T DK0495265T3 (da) | 1990-12-31 | 1991-12-30 | Syrelabile koblingsmolekyler |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5306809A (da) |
| EP (1) | EP0495265B1 (da) |
| JP (1) | JPH04334377A (da) |
| KR (1) | KR920012063A (da) |
| AT (1) | ATE109476T1 (da) |
| AU (1) | AU646121B2 (da) |
| CA (1) | CA2058595A1 (da) |
| DE (1) | DE69103255T2 (da) |
| DK (1) | DK0495265T3 (da) |
| ES (1) | ES2061166T3 (da) |
| FI (1) | FI101678B1 (da) |
| HU (1) | HUT60484A (da) |
| IE (1) | IE65406B1 (da) |
| NO (1) | NO180417C (da) |
| NZ (1) | NZ241217A (da) |
| PT (1) | PT99954B (da) |
| ZA (1) | ZA9110203B (da) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5505931A (en) * | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| EP0638583A1 (en) * | 1993-08-13 | 1995-02-15 | Hoechst Aktiengesellschaft | Aminosugar active substances, a process for their preparation and use as pharmaceuticals |
| DE4433890C2 (de) * | 1994-09-22 | 1999-02-18 | Deutsches Krebsforsch | Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein |
| ATE234635T1 (de) * | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| DE19636889A1 (de) * | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
| US6030997A (en) * | 1998-01-21 | 2000-02-29 | Eilat; Eran | Acid labile prodrugs |
| US6800616B2 (en) * | 1998-02-26 | 2004-10-05 | Supergen, Inc. | Treatment of HIV infections |
| CA2248592A1 (en) * | 1998-08-31 | 2000-02-29 | Christopher D. Batich | Microspheres for use in the treatment of cancer |
| TWI242000B (en) * | 1998-12-10 | 2005-10-21 | Univ Southern California | Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use |
| US6140015A (en) * | 1998-12-10 | 2000-10-31 | International Business Machines Corporation | Photoresist compositions with pendant polar-functionalized aromatic groups and acid-labile branching |
| CA2358420C (en) * | 1999-03-11 | 2010-03-16 | Ardenia Investments Ltd. | New compounds for the treatment of cancer |
| US6706892B1 (en) * | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
| BRPI0003386B8 (pt) * | 2000-08-08 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas |
| HUP0303719A2 (hu) * | 2000-10-16 | 2004-03-01 | Neopharm, Inc. | Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| EP1392359B2 (en) | 2001-05-11 | 2013-03-13 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
| GB0116143D0 (en) * | 2001-07-02 | 2001-08-22 | Amersham Pharm Biotech Uk Ltd | Chemical capture reagent |
| KR100507968B1 (ko) * | 2001-08-18 | 2005-08-17 | 한국과학기술연구원 | 자기집합체를 형성하는 항암제-키토산 복합체 및 그의제조방법 |
| CA2822457C (en) * | 2001-12-14 | 2016-03-08 | The University Of Wyoming | Methods and compositions for controlled resease of drugs |
| US8361464B2 (en) | 2002-03-01 | 2013-01-29 | Immunomedics, Inc. | Anthracycline-Antibody Conjugates for Cancer Therapy |
| US20050069551A1 (en) * | 2002-03-08 | 2005-03-31 | Emory University | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis |
| JP2005529080A (ja) * | 2002-03-08 | 2005-09-29 | エモリー ユニバーシティ | 腫瘍の増殖および脈管形成のサプレッサとしての新規のクルクミノイド−第ＶＩＩａ因子構築物 |
| WO2003100081A2 (en) * | 2002-05-24 | 2003-12-04 | Mirus Corporation | Biologically active maleamic acid derivatives with labile amide bonds |
| CN1733314A (zh) * | 2004-08-11 | 2006-02-15 | 张阳德 | 半乳糖化白蛋白磁性阿霉素纳米粒的制备方法 |
| EP1809671B1 (en) * | 2004-11-09 | 2014-07-16 | University Of Southern California | CpG/antibody conjugate against cancer |
| ES2408704T3 (es) | 2005-01-05 | 2013-06-21 | Biogen Idec Ma Inc. | Moléculas de unión a Cripto |
| KR20090091145A (ko) | 2006-10-27 | 2009-08-26 | 웨이-치앙 션 | 지질화된 인터페론 및 이의 용도 |
| US9090693B2 (en) * | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| ES2542152T3 (es) * | 2007-03-15 | 2015-07-31 | Ludwig Institute For Cancer Research Ltd. | Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas |
| CN108424454B (zh) | 2007-08-14 | 2022-05-31 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
| WO2010011684A2 (en) * | 2008-07-21 | 2010-01-28 | The Regents Of The University Of California | Prodrug and fluoregenic compositions and methods for using the same |
| JP5472288B2 (ja) * | 2009-03-17 | 2014-04-16 | 国立大学法人 東京大学 | タンパク質の電荷調節剤、及びタンパク質内包高分子ミセル複合体 |
| US8535948B2 (en) * | 2009-03-26 | 2013-09-17 | Institute For Systems Biology | Method to determine protein interaction sites |
| JP2012531212A (ja) | 2009-07-03 | 2012-12-10 | アビペップ ピーティーワイ リミテッド | イムノコンジュゲート及びその作製方法 |
| US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| SG181814A1 (en) | 2009-12-23 | 2012-07-30 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them 2 |
| RU2013103763A (ru) | 2010-07-02 | 2014-08-10 | Ангиохем Инк. | Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения |
| US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
| CN103890246A (zh) | 2011-08-18 | 2014-06-25 | 亲和生物科学公司 | 可溶性多肽 |
| MX350378B (es) | 2012-01-10 | 2017-09-05 | Biogen Ma Inc | Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica. |
| GB201202268D0 (en) | 2012-02-09 | 2012-03-28 | Medical Res Council | Intracellular immunity |
| WO2014057436A2 (en) | 2012-10-10 | 2014-04-17 | Adamed Sp. Z O.O. | Anticancer conjugate |
| CA2895284A1 (en) | 2013-02-07 | 2014-08-14 | Immunomedics, Inc. | Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
| WO2014141094A1 (en) | 2013-03-14 | 2014-09-18 | Adamed Sp. Z O.O. | Anticancer conjugate |
| WO2015123595A1 (en) | 2014-02-14 | 2015-08-20 | The Regents Of The University Of California | Cyclic peroxides as prodrugs for selective delivery of agents |
| CN106999444B (zh) | 2014-10-03 | 2023-12-12 | 安吉尼科分子传输公司 | 完整的细菌衍生的囊泡对小分子化合物的增强装载 |
| BR102016018074A2 (pt) | 2015-08-07 | 2021-11-16 | ALX Oncology Inc. | Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica |
| WO2017027422A1 (en) | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
| CA3006313C (en) | 2015-11-24 | 2020-02-11 | Transfert Plus, S.E.C. | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy |
| US10800817B2 (en) | 2016-12-19 | 2020-10-13 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
| EP3554638B1 (en) | 2016-12-19 | 2022-02-02 | Morehouse School of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
| WO2020081174A1 (en) | 2018-10-16 | 2020-04-23 | Nant Holdings Ip, Llc | Alpha emitter compositions and methods |
| BR112021024003A2 (pt) | 2019-05-31 | 2022-04-19 | Alx Oncology Inc | Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico |
| AU2020394204A1 (en) | 2019-11-27 | 2022-06-02 | ALX Oncology Inc. | Combination therapies for treating cancer |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| US11180534B1 (en) | 2021-06-04 | 2021-11-23 | Morehouse School Of Medicine | Compositions and methods for treating SARS-CoV-2 infections |
| JP2025503700A (ja) * | 2022-01-14 | 2025-02-04 | レジェネロン ファーマシューティカルズ， インコーポレイテッド | ベルカリンａ誘導体及びその抗体薬物複合体 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4631190A (en) * | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4542225A (en) * | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4744981A (en) * | 1985-10-17 | 1988-05-17 | Neorx Corporation | Trichothecene antibody conjugates |
| US4997913A (en) * | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
| US5140013A (en) * | 1989-11-28 | 1992-08-18 | Universite Laval | Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers |
-
1991
- 1991-12-27 FI FI916131A patent/FI101678B1/fi active
- 1991-12-27 JP JP3361486A patent/JPH04334377A/ja active Pending
- 1991-12-28 HU HU914133A patent/HUT60484A/hu unknown
- 1991-12-30 AU AU90098/91A patent/AU646121B2/en not_active Ceased
- 1991-12-30 ZA ZA9110203A patent/ZA9110203B/xx unknown
- 1991-12-30 DK DK91203439.4T patent/DK0495265T3/da active
- 1991-12-30 ES ES91203439T patent/ES2061166T3/es not_active Expired - Lifetime
- 1991-12-30 EP EP91203439A patent/EP0495265B1/en not_active Expired - Lifetime
- 1991-12-30 IE IE456791A patent/IE65406B1/en not_active IP Right Cessation
- 1991-12-30 DE DE69103255T patent/DE69103255T2/de not_active Expired - Fee Related
- 1991-12-30 CA CA002058595A patent/CA2058595A1/en not_active Abandoned
- 1991-12-30 PT PT99954A patent/PT99954B/pt not_active IP Right Cessation
- 1991-12-30 AT AT91203439T patent/ATE109476T1/de active
- 1991-12-30 KR KR1019910025982A patent/KR920012063A/ko not_active Ceased
- 1991-12-31 US US07/815,671 patent/US5306809A/en not_active Expired - Fee Related
-
1992
- 1992-01-02 NO NO920040A patent/NO180417C/no unknown
- 1992-01-06 NZ NZ241217A patent/NZ241217A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR920012063A (ko) | 1992-07-25 |
| AU646121B2 (en) | 1994-02-10 |
| IE65406B1 (en) | 1995-10-18 |
| NO180417B (no) | 1997-01-06 |
| DE69103255T2 (de) | 1994-12-08 |
| PT99954B (pt) | 1999-06-30 |
| DE69103255D1 (de) | 1994-09-08 |
| EP0495265A1 (en) | 1992-07-22 |
| ES2061166T3 (es) | 1994-12-01 |
| ATE109476T1 (de) | 1994-08-15 |
| JPH04334377A (ja) | 1992-11-20 |
| US5306809A (en) | 1994-04-26 |
| CA2058595A1 (en) | 1992-07-01 |
| IE914567A1 (en) | 1992-07-01 |
| NO920040D0 (no) | 1992-01-02 |
| FI101678B (fi) | 1998-08-14 |
| PT99954A (pt) | 1993-06-30 |
| FI916131A0 (fi) | 1991-12-27 |
| NO180417C (no) | 1997-04-16 |
| NO920040L (no) | 1992-07-01 |
| ZA9110203B (en) | 1993-01-27 |
| FI101678B1 (fi) | 1998-08-14 |
| HU914133D0 (en) | 1992-03-30 |
| AU9009891A (en) | 1993-01-28 |
| EP0495265B1 (en) | 1994-08-03 |
| FI916131A7 (fi) | 1992-07-01 |
| NZ241217A (en) | 1993-12-23 |
| HUT60484A (en) | 1992-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0495265T3 (da) | Syrelabile koblingsmolekyler | |
| US4880935A (en) | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates | |
| MXPA03010432A (es) | Inmunoconjugados del anticuerpo cd44 citotoxico. | |
| ATE294592T1 (de) | Thioether enthaltende konjugate | |
| KR900002803A (ko) | 세포독성 약물 결합체 | |
| FI912285A0 (fi) | Nya bifunktionella kopplingsfoereningar, konjugat och foerfaranden foer framstaellning av dessa. | |
| US4263279A (en) | Pharmaceutically active compositions containing adriamycin and daunomycin | |
| DK5982A (da) | Fremgangsmaade til fremstilling af immunoglobulinkonjagater | |
| ES2095840T3 (es) | Conjugado de anticuerpo-farmaco. | |
| KR950704256A (ko) | 2―히드라지노피리딘 유도체를 사용하는 분자표시방법(molecule labelling using 2―hydrazinopyridine derivatives) | |
| DK0384769T3 (da) | Mærkning af proteiner | |
| HU184736B (en) | Process for preparing anticarcinogenic immunoglobuline derivatives | |
| FI915780A0 (fi) | Maerktae, modifierade oligonukleotider. | |
| FI102077B1 (fi) | Magneettisia proteiinikonjugaatteja, menetelmä niiden valmistamiseksi ja niiden käyttö | |
| WO2004041307A3 (en) | Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy | |
| HU9500585D0 (en) | Hepatotropic conjugates of antiviral drugs, carriers thereof and pharmaceutical compositions containing them |